Navigation Links
MIT works toward novel therapeutic device
Date:10/22/2007

CAMBRIDGE, Mass.-MIT and University of Rochester researchers report important advances toward a therapeutic device that has the potential to capture cells as they flow through the blood stream and treat them. Among other applications, such a device could zapp cancer cells spreading to other tissues, or signal stem cells to differentiate.

Their concept leverages cell rolling, a biological process that slows cells down as they flow through blood vessels. As the cells slow, they adhere to the vessel walls and roll, allowing them to sense signals from nearby tissues that may be calling them to work. Immune cells, for example, can be slowed and summoned to battle an infection.

Through mimicking a process involved in many important physiological and pathological events, we envision a device that can be used to selectively provide signals to cells traveling through the bloodstream, said Jeffrey M. Karp of the Harvard-MIT Division of Health Sciences and Technology. This technology has applications in cancer and stem cell therapies and could be used for diagnostics of a number of diseases.

The team, led by Karp, started with technology to induce cell rolling for research. With an implantable therapeutic device in mind, they improved that cell rolling technology to make it safe, more stable and longer lasting.

The improvements are described in the October 20 online issue of the journal Langmuir, published by the American Chemical Society.

In the body, P-selectin and other selectin proteins regulate cell rolling in blood vessels. When P-selectin is present on a vessel's inner wall, cells that are sensitive to it will stick to that patch and begin to roll across it.

To induce rolling in the laboratory, the original technology weakly adheres P-selectin to a glass surface and flows cells across it. This surface treatment remains stable for several hours then breaks down. While this method is useful for experiments, it's not good for long-term stability, said Karp. An implantable device needs a coating that lasts weeks or even months so that patients won't need to come in frequently for replacements.

To improve the technology, the team experimented with several chemical methods to immobilize P-selectin on a glass surface. They identified a polyethelene glycol (PEG) coating that strongly bonded to P-selectin. This coating is also non-fouling, meaning it does not react with or accumulate other proteins, so it is potentially safe for use in an implant.

P-selectin remains stable on this coating for longer than the original technology. In tests with microspheres coated with a molecule that interacts with P-selectin, these spheres slowed down significantly as they flowed over the surface coated with layers of PEG and P-selectin. The effect was stable past four weeks, the longest the devices have been tested.

To validate that this technology works with cells that are sensitive to P-selectin, the team flowed neutrophils (white blood cells) across the coated surface. They too slowed and rolled on surfaces treated with the new coating, and the effect again lasted for at least four weeks.

The next step is translating these results to animal studies and using the technology to slow and capture stem cells and cancer cells circulating in the blood stream.

Ultimately CellTraffix, Inc., a sponsor of this technology and its licensee, wants to apply the technique to a device that is either implanted into the blood stream or appended as a shunt. In addition to PEG and selectin molecules, the device would also include a therapeutic agent. Such an agent would interact only with certain cells for a specific purpose.

According to University of Rochester biomedical engineering professor Michael King, who developed the concept for adhesive capture and reprogramming of cells, the device could, for example, slow down metastatic, or spreading, cancer cells and kill them.


'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Fireworks can spell death for asthmatic children
2. How a mans mind really works
3. Drug Combo Works Better for children with ADHD, Tics
4. How brain works
5. Meditation Works Medically
6. A first in Liver Transplant in India – Networking works wel
7. Warts: Spanner in Lovers Works!
8. Shot Supply: Reduced Dosage of Seasonal flu Vaccine, Works!
9. Subliminal Advertising works
10. De-addiction Drug Works For Alcoholics Too
11. Vagal Nerve Stimulation Works To Treat Severe Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 02, 2016 , ... Dr. Philip Shindler, dentist in Agoura Hills , ... the past, many necessary dental treatments could require multiple appointments to complete. This could ... extra chair time. Not only could this be inconvenient, but it could also be ...
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist , Dr. Ramin ... Dr. Assili to receive any dental extraction treatment for $40 off the regular price. ... 2016. With the lower price, patients can more easily afford extractions to eliminate teeth ...
(Date:5/2/2016)... ... May 02, 2016 , ... This week Omega Institute, a premier nonprofit educational ... runs through October. Omega is offering a record 370 in-person workshops and new ... been such widespread interest in or need for the knowledge and skills we’ve been ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... a new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies for ... results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also known as ... kidneys, liver and pancreas. If not properly addressed, visceral fat can lead to ... Medicine, Medical Oncology and Palliative Care, warns against the dangers of visceral fat. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
(Date:4/28/2016)... --  Acsis , a leading provider of supply chain ... and advisory firm IDC has named it a " ... Track and Trace Software 2016 Vendor Assessment (doc # ... the capabilities and business strategies of 10 vendors in ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... April 27, 2016 ... Forums in Zürich gab Strekin AG den ... STR001 zur Erhaltung des Resthörvermögens von Patienten, ... Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden ... STR001 wird während der Operation direkt ins ...
Breaking Medicine Technology: